N, number of tumor samples containing corresponding EGFR mutation; (i) Comparison of patient ages across different EGFR mutation statuses in the XWLC cohort, N, number of tumor samples containing corresponding EGFR mutation; (j–k) Presentation of overall survival (OS), (j) and progression-free interval (PFI), (k) analysis across different EGFR mutation statuses in the TCGA-LUAD cohort, Logrank test was used to calculate p-values; (l) Evaluation of kinase activities by KSEA in tumors across different EGFR mutation statuses in the XWLC cohort. Here, EGFR is linked to neoplasm.